

More from ADA ▼

OXFORD UNIVERSITY LIB SVCS


[Subscribe](#) [Log in](#) [Log out](#)


[Advanced Search](#)

[Home](#) [Current](#) [Browse](#) [Info](#) [Reprints/Reuse](#) [Advertising](#)
[Subscriptions](#) [Alerts](#) [Podcast](#) [Submit](#)

Late Breaking Poster Session

Advertisement

Impact of SGLT2 Inhibitors (SGLT2i) on Cardiovascular (CV) Risk and Estimated Glomerular Filtration Rate (eGFR) in the EXSCEL Placebo Group

LINDSAY CLEGG, HIDDO L. HEERSPINK, ROBERT C. PENLAND, WEIFENG TANG, DAVID W. BOULTON, SRINIVAS BACHINA, ROBERT D. FOX, PETER FENICI, MARCUS THURESSON, ROBERT J. MENTZ, ADRIAN F. HERNANDEZ, M. ANGELYN BETHEL and RURY R. HOLMAN

[+ Author Affiliations](#)

Diabetes 2018 Jul; 67(Supplement 1): -
<https://doi.org/10.2337/db18-130-LB>

[← Previous](#)
[Article](#)
[Figures & Tables](#)
[Info & Metrics](#)

Abstract

SGLT2i, empagliflozin and canagliflozin, have been shown to reduce the incidence of major adverse CV events (MACE), all-cause mortality (ACM) and renal events in CV outcomes trials (CVOTs), with robust real-world evidence (RWE) suggesting class effect benefits. In the exenatide CVOT EXSCEL, ~10% of patients took an SGLT2i with ~5% use of dapagliflozin (DAPA). Effects of all SGLT2i, and DAPA alone, on MACE, ACM, and eGFR were analyzed in EXSCEL participants randomized to placebo.



In this Issue

July 2018,
67(Supplement 1)

[Table of Contents](#)
[Index by Author](#)
[Abstract PDFs](#)

[Sign up to receive current issue alerts](#)

View Selected Citations (0)

[Article Alerts](#)

[Email Article](#)

[Share](#)

[Request Permissions](#)

[Tweet](#)

[More from ADA](#) ▼

OXFORD UNIVERSITY LIB SVCS

[Subscribe](#) [Log in](#) [Log out](#)

characteristics before SGLT2i initiation. Subsequent time-to-first adjudicated MACE and ACM were compared using a Cox regression. Decline in eGFR over time (slope) was quantified in the matched cohorts using a mixed model repeated measurement (MMRM) analysis.

SGLT2i overall, and DAPA alone, numerically decreased the MACE hazard ratio, and SGLT2i significantly reduced the ACM risk (Table). The eGFR slope was improved significantly for SGLT2i overall and DAPA alone (Table).

This post-hoc EXSCEL analysis supports a beneficial class effect for SGLT2i on MACE, ACM, and renal function, consistent with published CVOTs, Real-World data, and for DAPA alone. DECLARE, the ongoing DAPA CVOT, will complete in 2018.

[View inline](#) | [View popup](#)

Disclosure L. Clegg: Employee; Self; AstraZeneca.

H.L. Heerspink: Consultant; Self; AbbVie Inc., AstraZeneca. Advisory Panel; Self; Boehringer Ingelheim GmbH. Consultant; Self; Janssen Research & Development, Fresenius SE & Co. KGaA. Advisory Panel; Self; Merck & Co., Inc.. Consultant; Self; Mitsubishi Tanabe Pharma Corporation. **R.C.**

Penland: Employee; Self; AstraZeneca. Stock/Shareholder; Self; Novartis Pharmaceuticals Corporation. **W. Tang:** Employee; Self; AstraZeneca.

D.W. Boulton: Employee; Self; AstraZeneca. Stock/Shareholder; Self; Bristol-Myers Squibb Company. **S. Bachina:** Employee; Self; AstraZeneca.

R.D. Fox: None. **P. Fenici:** Employee; Self; AstraZeneca. **M. Thuresson:** Consultant; Self; AstraZeneca. **R.J. Mentz:** Research Support; Self; AstraZeneca, GlaxoSmithKline plc., Merck & Co., Inc.

A.F. Hernandez: Research Support; Self; AstraZeneca, GlaxoSmithKline plc., Merck & Co., Inc..

[Selected Citations](#)

Jump to section

- [Article](#)
- [Figures & Tables](#)
- [Info & Metrics](#)

▼ Related Articles

No related articles found.[Google Scholar](#)

▶ Cited By...

▶ More in this TOC Section

▶ Similar Articles

More from ADA ▼

OXFORD UNIVERSITY LIB SVCS

[Subscribe](#) [Log in](#) [Log out](#)

Pharmaceuticals Corporation. **M. Bethel:** Research Support; Self; AstraZeneca, Merck Sharp & Dohme Corp., Merck Serono. Advisory Panel; Self; Boehringer Ingelheim Pharmaceuticals, Inc.. Consultant; Self; Novo Nordisk Inc.. Advisory Panel; Self; AstraZeneca. Other Relationship; Self; Sanofi. Consultant; Self; Theracos, Inc.. Research Support; Self; GlaxoSmithKline plc. **R.R. Holman:** Research Support; Self; AstraZeneca, Merck & Co., Inc., Bayer AG. Advisory Panel; Self; Elcelyx Therapeutics, Inc., Novartis AG, Novo Nordisk A/S. Other Relationship; Self; Bayer AG. Advisory Panel; Self; Merck & Co., Inc.. Other Relationship; Self; AstraZeneca.

© 2018 by the American Diabetes Association.

<http://www.diabetesjournals.org/content/license>

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at <http://www.diabetesjournals.org/content/license>.

We recommend

Renal Outcomes in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) YULIYA LOKHNYGINA et al., Diabetes, 2018	ASCO: Complete Lymph Node Dissection Does Not Improve Survival in Patients With Melanoma and Micrometastases Univadis (UK), 2015
Lower Risk of CV Events and Death Associated with Initiation of SGLT2 vs. DPP-4 Inhibitors—Analysis from the CVD-REAL 2 Study MARCUS THURESSON et al., Diabetes, 2018	Cancer Risk From Diabetes Drugs Unproven, Say AACE/ACE Miriam E. Tucker et al., Medscape
Cardiovascular Event Hazards over Time in TECOS M. ANGELYN BETHEL et al., Diabetes, 2018	Potential modification of the UKPDS risk engine and evaluation of macrovascular event rates in controlled clinical trials Fred Yang et al., Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2013
EXSCEL—Once-Weekly Exenatide Reduces Medical Resource Utilization in	

More from ADA ▼

OXFORD UNIVERSITY LIB SVCS



[Subscribe](#) [Log in](#) [Log out](#)

Modulation of Dapagliflozin-Associated Genital Tract Infections by Saxagliptin—A Pooled Safety Analysis
 STEFANO DEL PRATO et al., Diabetes, 2018

Latest Developments and Expert Outlook On Management of Psoriatic Arthritis
 M. Elaine Husni et. al., myCME, 2018

Powered by **TREND MD**

I consent to the use of Google Analytics and related cookies across the TrendMD network (widget, website, blog). [Learn more](#)

[← Previous](#)

[^ Back to top](#)

Navigate

- Current Issue
- Online Ahead of Print
- Scientific Sessions Abstracts
- Collections
- Archives
- Submit
- Subscribe
- Email Alerts
- RSS Feeds

More Information

- About the Journal
- Instructions for Authors
- Journal Policies
- Reprints and Permissions
- For Advertisers
- Privacy Policy: ADA Journals
- Copyright Notice/Public Access Policy
- Contact Us

Other ADA Resources

- Diabetes Care
- Clinical Diabetes
- Diabetes Spectrum
- Standards of Medical Care in Diabetes
- BMJ Open - Diabetes Research & Care
- Scientific Sessions Abstracts
- Professional Books
- Diabetes Forecast

- DiabetesJournals.org
- Diabetes Core Update
- ADA's DiabetesPro
- ADA Member Directory
- Diabetes.org

Advertisement

© 2019 by the American Diabetes Association. Diabetes Print ISSN: 0012-1797, Online ISSN: 1939-327X.